Acura Pharmaceuticals Inc. recently launched Nexafed, its version of pseudoephedrine that uses the biotech's abuse-deterrent technology to help disrupt the drug's conversion to methamphetamine. Acura is focusing its marketing message for the over-the-counter decongestant on pharmacists.